Kamada Ltd. (KMDA) P/E Ratio History
UndervaluedTrading at 19.4x vs 5Y avg 25.6x · 45th percentile · Below historical baseline · Data 2013–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Kamada Ltd. (KMDA) trades at a price-to-earnings ratio of 19.4x, with a stock price of $7.19 and trailing twelve-month earnings per share of $0.34.
The current P/E is 24% below its 5-year average of 25.6x. Over the past five years, KMDA's P/E has ranged from a low of 10.8x to a high of 70.9x, placing the current valuation at the 45th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, KMDA is roughly in line with its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, KMDA trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KMDA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KMDA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
KMDA P/E vs Peers
Vaccines and biodefense products peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 14.3 | - | -26% | |
| $6B | 11.2 | - | +148%Best | |
| $8B | 10.1 | - | +143% | |
| $4B | 9.6Lowest | - | +68% | |
| $15B | 21.1 | 0.87Best | -39% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
KMDA Historical P/E Data (2013–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $8.34 | $0.35 | 23.9x | -98% |
| FY2025 Q4 | Dec 31 2025 | $7.06 | $0.35 | 20.2x | -98% |
| FY2025 Q3 | - | $6.94 | $0.36 | 19.3x | -98% |
| FY2025 Q2 | Jun 30 2025 | $7.75 | $0.34 | 22.8x | -98% |
| FY2025 Q1 | Mar 31 2025 | $6.61 | $0.29 | 22.8x | -98% |
| FY2024 Q4 | - | $6.09 | $0.26 | 23.4x | -98% |
| FY2024 Q3 | Sep 30 2024 | $5.37 | $0.28 | 18.9x | -98% |
| FY2024 Q2 | Jun 30 2024 | $4.96 | $0.27 | 18.2x | -98% |
| FY2024 Q1 | Mar 31 2024 | $5.61 | $0.23 | 24.2x | -98% |
| FY2023 Q4 | Dec 31 2023 | $6.12 | $0.15 | 40.6x | -96% |
| FY2023 Q3 | Sep 30 2023 | $5.34 | $0.12 | 43.3x | -96% |
| FY2023 Q2 | Jun 30 2023 | $5.28 | $0.07 | 70.9x | -93% |
| FY2021 Q3 | - | $5.30 | $0.10 | 53.0x | -95% |
| FY2021 Q2 | Jun 30 2021 | $5.82 | $0.27 | 21.6x | -98% |
| FY2021 Q1 | Mar 31 2021 | $6.19 | $0.35 | 17.7x | -98% |
| FY2020 Q4 | - | $6.48 | $0.41 | 15.8x | -98% |
| FY2020 Q3 | Sep 30 2020 | $8.36 | $0.50 | 16.7x | -98% |
| FY2020 Q2 | - | $7.76 | $0.49 | 15.8x | -98% |
| FY2020 Q1 | - | $5.83 | $0.54 | 10.8x | -99% |
| FY2019 Q4 | - | $6.83 | $0.54 | 12.6x | -99% |
| FY2019 Q3 | Sep 30 2019 | $5.13 | $0.85 | 6.0x | -99% |
| FY2019 Q2 | Jun 30 2019 | $5.52 | $0.65 | 8.5x | -99% |
| FY2019 Q1 | Mar 31 2019 | $5.73 | $0.64 | 9.0x | -99% |
| FY2018 Q4 | Dec 31 2018 | $5.00 | $0.55 | 9.1x | -99% |
| FY2018 Q3 | Sep 30 2018 | $6.20 | $0.27 | 23.0x | -98% |
| FY2018 Q2 | Jun 30 2018 | $5.20 | $0.32 | 16.0x | -98% |
| FY2018 Q1 | Mar 31 2018 | $4.60 | $0.31 | 14.6x | -99% |
| FY2017 Q4 | Dec 31 2017 | $4.75 | $0.17 | 27.3x | -97% |
| FY2013 Q3 | Sep 30 2013 | $15.30 | $0.00 | 25500.0x | +2463% |
| FY2013 Q2 | Jun 30 2013 | $11.16 | $0.00 | 3720.0x | +274% |
Average P/E for displayed period: 994.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KMDA — Frequently Asked Questions
Quick answers to the most common questions about buying KMDA stock.
What is KMDA's P/E ratio?
Kamada Ltd. (KMDA) trailing twelve-month P/E ratio is 19.4x, based on TTM diluted EPS of $0.34. The 5-year average P/E is 25.6x and the historical range spans 10.8x to 70.9x.
Is KMDA stock overvalued or undervalued?
KMDA trades at 19.4x P/E, below its 5-year average of 25.6x. At the 45th percentile of its historical range (10.8x–70.9x), the stock is priced at a discount to its own history.
Is KMDA stock expensive?
No, KMDA is not expensive on a historical basis. The current P/E of 19.4x is below the 5-year average of 25.6x and sits at the 45th percentile of its valuation range.
What is KMDA's historical P/E range?
Over the past 5 years, KMDA's P/E ratio has ranged from 10.8x to 70.9x, with a median of 21.6x and an average of 25.6x. The current P/E of 19.4x places the stock at the 45th percentile of this range. Full historical data spans 2013–2026.
How does KMDA's P/E compare to the S&P 500?
KMDA trades at 19.4x P/E versus the S&P 500 median of 24.3x. The 20% discount to the market suggests lower growth expectations or perceived higher risk.
How does KMDA's valuation compare to Healthcare peers?
Kamada Ltd. P/E of 19.4x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is KMDA's PEG ratio?
KMDA PEG ratio is N/A, based on a P/E of 19.4x and EPS growth of 48.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is KMDA's earnings yield?
KMDA earnings yield is 5.15%, the inverse of its 19.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.